Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P1118 | DOI: 10.1530/endoabs.35.P1118

ECE2014 Poster Presentations Thyroid Cancer (70 abstracts)

Clinical and biochemical characteristics of papillary thyroid cancer according to the presence of BRAF (V600E) mutation

Amelia Oleaga 1 , Fernando Goñi 1 , Miguel Paja 1 , Maite Pérez de Ciriza 1, , Eider Etxeberría 1 , Laura Calles 1 , Estíbaliz Ugarte 1 , Aitziber Ugalde 2 & J Ramón Elorza 1

1Endocrinology Department Basurto Hospital, Bilbao, Vizcaya, Spain; 2Pathology Department, Basurto Hospital, Bilbao, Vizcaya, Spain.

Introduction: BRAF (V600E) mutation is the most frequent detected genetic change in papillary thyroid cancer (PTC). Its presence has been related to aggressive clinical and pathological features. Therefore, BRAF mutation has drawn considerable interest as a potential prognostic factor for PTC. The presence of the mutation confers the tumour a disability to uptake RAI, diminishing the therapeutic tools. However if this feature is related to some kind of tumour dedifferentiation is not known. The aim of this study was to explore if there were any differences in preoperative thyroglobulin (PTg) levels and the presence of autoimmunity (PTg Ab), among patients harbouring the mutation and those who did not.

Methods: We evaluated 62 patients (51 females) with pathological diagnosis of PTC. All of them underwent total thyroidectomy, 55 central lymph node dissection, and 13 lateral neck dissection as well. DNA was extracted from neoplastic cells and BRAF mutation was detected by PCR and sequencing. Analysis included age, preoperatively TSH, PTg and PTg Ab, tumour size and thyroid weight.

Results: The prevalence of the BRAF mutation (BRAF+) in our patients was 51.6%. According to sex, 45.5% males and 53% females were BRAF+ (P=0.68).

Mean age was 48.9 years in BRAF+ vs 50.4 in BRAF−(P=0.71).

Mean tumour size was 16.8 mm in BRAF+ vs19.4 in BRAF−(P=0.43).

Median thyroid weight was 23 g in BRAF− and 19.5 g in BRAF+ (P=0.31).

Mean TSH level was 2.33 μ/l in BRAF− vs 3.26 in BRAF+ (P=0.14).

PTg level was 355.6 ng/mL in BRAF− vs 154.5 ng/mL in BRAF+ (P=0.13).

PTg Ab were positive in 29.6% in BRAF− vs 33.3% in BRAF+ patients (P=0.6).

Conclusions: In our series, harbouring BRAF mutation, neither implies less production of Tg by the tumour, nor higher frequency of autoimmunity, although there is a tendency towards less PTg concentration and smaller tumour size. Nevertheless higher PTg levels may be related to a trend to heavier thyroid gland. In view of these results, and considering the small size of the sample, we cannot conclude that the presence of BRAF mutation, involves any grade of dedifferentiation in PTC.

Article tools

My recent searches

No recent searches.